Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFACT 3: F/TAF PrEP and Hormone Therapy Interaction in Transgender Women
NCT04590417Active, not recruiting
- Sponsor
- Thai Red Cross AIDS and Infectious Diseases Research Centre
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Open-label trial of emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Thai Red Cross AIDS and Infectious Diseases Research Centre. Primary endpoint: Plasma estradiol at 9 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04590417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590417.